General Information:

Id: 6,456 (click here to show other Interactions for entry)
Diseases: Cancer
Diabetes mellitus, type II - [OMIM]
Insulin resistance
Mammalia
review
Reference: Viollet B et al.(2012) Cellular and molecular mechanisms of metformin: an overview Clin. Sci. 122: 253-270 [PMID: 22117616]

Interaction Information:

Comment AGEs (advanced glycation end-products) are important contributors of diabetic complications by promoting cellular oxidative stress and inflammation. It has been reported that metformin can reduce the synthesis of AGEs and their specific cell receptor expression independently of its antihyperglycaemic effects. Although done in vitro, this suggests that metformin can directly modulate the glycation process.
Formal Description
Interaction-ID: 61307

drug/chemical compound

Advanced glycation end-product

increases_activity of

Comment AGEs (advanced glycation end-products) are important contributors of diabetic complications by promoting cellular oxidative stress and inflammation. It has been reported that metformin can reduce the synthesis of AGEs and their specific cell receptor expression independently of its antihyperglycaemic effects. Although done in vitro, this suggests that metformin can directly modulate the glycation process.
Formal Description
Interaction-ID: 61308

drug/chemical compound

Advanced glycation end-product

increases_activity of

Comment AGEs (advanced glycation end-products) are important contributors of diabetic complications by promoting cellular oxidative stress and inflammation. It has been reported that metformin can reduce the synthesis of AGEs and their specific cell receptor expression independently of its antihyperglycaemic effects. Although done in vitro, this suggests that metformin can directly modulate the glycation process.
Formal Description
Interaction-ID: 61309

drug/chemical compound

Metformin

decreases_quantity of

drug/chemical compound

Advanced glycation end-product

Drugbank entries Show/Hide entries for Metformin